2018 Drug Data Trends

The story of drug plans is increasingly two-sided: on the one side are higher-cost specialty drugs, which laid claim to 27% of eligible costs in 2017 for just 1% of claimants; on the other side are traditional non-specialty drugs, where annual growth rates for costs [...]

Continue reading